In a recent Chinese longitudinal cohort, anti-TIF1-γ Ab was associated with an increased risk of cancer compared to the general population (standardized incidence ratio = 17.28, 95% CI (11.94–24.24)) [10]. Here, TRIM33 is linked to cancer.